• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Suvorexant May Prevent Delirium in Hospitalized Patients

Suvorexant May Prevent Delirium in Hospitalized Patients

May 21, 2021
Alexander Thompson, MD, MBA, MPH
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Alexander Thompson, MD, MBA, MPH Dr. Thompson has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Hatta K et al, J Clin Psychiatry 2017;78(8):e970–e979; Hatta K et al, J Clin Psychiatry 2019;81(1):19m12865

Delirium is an acute confusional state that occurs frequently in older hospitalized patients, especially those with serious illness in the ICU. We try our best to prevent it because it is associated with worse medical outcomes, including mortality. Since one of the hallmarks of delirium is interrupted sleep, sedative-hypnotics are a natural treatment option. Unfortunately, benzodiazepines can worsen delirium. Non-benzodiazepine hypnotics such as ramelteon (a melatonin receptor agonist) and melatonin have shown promise at preventing delirium in small clinical trials. Recently, two trials examined whether a novel hypnotic, suvorexant (an orexin receptor antagonist), prevents delirium in patients at risk.

In the first study, 72 acute hospitalized patients, ages 65–89, were randomized to either suvorexant (15 mg given at 9 pm) or placebo for 3 days. The patients were followed for 7 days, starting the day after the drug was first given. Six placebo-receiving patients became delirious, while no suvorexant patients became delirious (17% vs 0%; p = 0.025). There was no difference in subjective or clinician-rated sleep parameters (such as total minutes of sleep) between the two groups.

The second study was a non-randomized “real-world” follow-up study examining delirium incidence in hospitalized patients given ramelteon (8 mg/day), suvorexant (15 mg/day), or both, compared to patients who chose to take neither. Those who took ramelteon and/or suvorexant developed delirium less frequently than those who took neither (63/401 = 16% vs 30/125 = 24% [RR 1.5]).

Researchers also studied patients who had been delirious the night before but were no longer confused the day the study started. Of this group, those who chose to take ramelteon and/or suvorexant also were less likely to develop delirium (133/333 = 40% vs 59/89 = 66% [RR 1.7]) and also showed sleep/wake cycle improvements at the end of the intervention.

CHPR’s Take
While suvorexant appears effective at preventing delirium, it’s unlikely to be a first-line agent in your hospitalized patients. Given its cost, it’s usually not on hospital formularies, and it can cause significant next-day sedation and even sleep paralysis and cataplexy, especially if used at higher doses (30–40 mg/day). For these reasons, if a sleeping agent is needed in your hospitalized patients, we recommend starting with ramelteon and only using suvorexant as a second- or third-line agent. Continue recommending common interventions to prevent delirium, including reorientation, uninterrupted sleep hours, hydration, avoidance of delirium-causing medications, and active treatment of underlying medical ­conditions.
Hospital Psychiatry
KEYWORDS delirium geriatric-psychiatry suvorexant
    Alexander Thompson, MD, MBA, MPH

    Confused About Acute Confusional States? A Primer on Delirium

    More from this author
    www.thecarlatreport.com
    Issue Date: May 21, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Capacity Assessments, CHPR, April/May/June 2021
    Finally, Effective Treatments for Tardive Dyskinesia
    Decisional Capacity
    Capacity Assessment in Pregnant Patients
    Suvorexant May Prevent Delirium in Hospitalized Patients
    SSRIs and Intracerebral Hemorrhage Risk
    Can Antidepressants Prolong Survival in Cancer Patients?
    Hyperprolactinemia: Effective Treatment With Aripiprazole
    Note From the Editor-in-Chief
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.